Finally, by demonstrating overexpression of Cmip and Gbp2 in the hepatocytes of patients with NAFLD, we suggest a reasonable possibility that both proteins could be effective targets for NAFLD prevention and treatment. The gene discussed is GBP2; the disease is metabolic dysfunction-associated steatotic liver disease.